Literature DB >> 19812351

Tamoxifen-induced adduct formation and cell stress in human endometrial glands.

Helén Andersson1, Malin Helmestam, Anna Zebrowska, Matts Olovsson, Eva Brittebo.   

Abstract

The beneficial effects of tamoxifen in the prevention and treatment of breast cancer are compromised by an increased risk of endometrial polyps, hyperplasia, and cancer. Tamoxifen is metabolized to an array of metabolites with estrogenic effects but also to reactive intermediates that may form protein and DNA adducts. The aim of this study was to investigate cellular [(3)H]tamoxifen adduct formation by light microscopic autoradiography and cell stress by immunohistochemical analysis of glucose-regulating protein 78 (GRP78), nuclear factor kappaB (NF-kappaB), and caspase 3 in human endometrial explants after short-term incubation with tamoxifen. The cellular expression of tamoxifen-metabolizing enzymes in human endometrial biopsy samples was also determined by immunohistochemistry. The results showed selective [(3)H]tamoxifen adduct formation in glandular and surface epithelia after incubation with a nontoxic concentration of [(3)H]tamoxifen (6 nM). There was also a selective expression of the endoplasmic reticulum stress chaperone GRP78 and activated caspase 3 at these sites after incubation with cytotoxic concentrations of tamoxifen (10-100 microM). The cell stress was preferentially observed in samples from women in the proliferative menstrual phase. No treatment-related expression of NF-kappaB was observed. Constitutive expression of the tamoxifen-metabolizing enzymes CYP1B1, CYP2A6, CYP2B6, CYP2C8/9/19, CYP2D6, and SULT2A1 in glandular and surface epithelia was shown, but there was a large interindividual variation. The colocalization of [(3)H]tamoxifen adducts, expression of GRP78, caspase 3, and tamoxifen-metabolizing enzymes in human glandular and surface epithelia suggest a local bioactivation of tamoxifen at these sites and that epithelial cells are early target sites for tamoxifen-induced cell stress.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19812351     DOI: 10.1124/dmd.109.029488

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1).

Authors:  Edwin J Squirewell; Xiaoyan Qin; Michael W Duffel
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

2.  The effects of endoxifen and other major metabolites of tamoxifen on the sulfation of estradiol catalyzed by human cytosolic sulfotransferases hSULT1E1 and hSULT1A1*1.

Authors:  Edwin J Squirewell; Michael W Duffel
Journal:  Drug Metab Dispos       Date:  2015-03-27       Impact factor: 3.922

3.  Tamoxifen-DNA adduct formation in monkey and human reproductive organs.

Authors:  Elena E Hernandez-Ramon; Nicole A Sandoval; Kaarthik John; J Mark Cline; Charles E Wood; Ruth A Woodward; Miriam C Poirier
Journal:  Carcinogenesis       Date:  2014-02-05       Impact factor: 4.944

4.  Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

Authors:  Ansgar Brüning; Klaus Friese; Alexander Burges; Ioannis Mylonas
Journal:  Breast Cancer Res       Date:  2010-07-01       Impact factor: 6.466

5.  Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death.

Authors:  Jayashree C Jagtap; D Parveen; Reecha D Shah; Aarti Desai; Dipali Bhosale; Ashish Chugh; Deepak Ranade; Swapnil Karnik; Bhushan Khedkar; Aaishwarya Mathur; Kumar Natesh; Goparaju Chandrika; Padma Shastry
Journal:  FEBS Open Bio       Date:  2014-11-21       Impact factor: 2.693

6.  Molecular mechanisms of tamoxifen-associated endometrial cancer (Review).

Authors:  Rong Hu; Leena Hilakivi-Clarke; Robert Clarke
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.